Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch
Vaxess will have exclusive rights to commercialize the MIMIX Flu Smart Release Patch in the US and Europe, while GC Pharma obtains rights for the South Korean market October 16, 2019 09:50 AM Eastern Daylight Time CAMBRIDGE, Mass. & SEOUL, South Korea–(BUSINESS WIRE)–GC Pharma, a leading manufacturer of influenza vaccines with a global reach, and Vaxess, an innovative biotechnology company developing the MIMIX smart release patch, have partnered to commercialize a highly effective, painless, and refrigeration-free flu vaccine in a new, convenient patch format. “GC Pharma is continually pushing the bounds of innovation in the influenza vaccine space” Tweet this Influenza viruses infect nearly 20 percent of the global population each year, leading to severe illness and hospitalization for millions of individuals. Suboptimal efficacy and challenges with patient compliance limit the public health impact of influenza vaccines despite their availability.
[Continue reading the full article on Business Wire website ]